Tanezumab
Phase 3Monoclonal antibody
PfizerTanezumab is used to treat moderate to severe chronic pain from osteoarthritis. It works by blocking a protein in the body that carries pain signals to the brain, helping reduce pain and improve movement.[1] Tanezumab is currently being investigated across 19 indications[3], with its most advanced program in Phase 3.[1]
Tanezumab is one of 403 biologic programs targeting Bone Metastasis. It is currently in Phase 3.
19
Indications
30
Total Trials
1
Active Trials
402
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Tanezumab
PfizerPhase 3
Epidiolex
Jazz PharmaceuticalsPreclinical
Cataflam
NovartisPreclinical
Lunesta
Akero TherapeuticsPreclinical
Glucophage
Boehringer IngelheimPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Naproxen Sodium
BayerPreclinical
Benadryl
PParkedale
Preclinical
Antidiabetic
FFederico II University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteoarthritis13 trials
Show 10 more trials
Low back pain4 trials
Arthritis2 trials
Peripheral Neuropathy1 trial
9 more indications
Medication1 trial
Prostatitis1 trial
Interstitial Cystitis1 trial
Bone Metastasis1 trial
Drug1 trial
Schwannoma1 trial
Endometriosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tanezumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]